NCT02223039已完成2 期
Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of AbGn-168H Administered by Intravenous Infusion to Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Double-blind, Placebo-controlled)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 28
- 主要终点
- 75% reduction in the Psoriasis Area Severity Index (PASI 75)
研究概览
简要总结
This is a phase II, randomised, double-blind, placebo-controlled, multiple-dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis. The objectives of this study is to investigate efficacy, safety, tolerability, and pharmacokinetics (PK) of multiple doses of AbGn-168H administered intravenously to patients with moderate to severe chronic plaque psoriasis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 75 (inclusive), males or females
- •Body weight < 140 kg
- •Patients with stable moderate to severe plaque-type psoriasis, no significant changes within the past 6 months, involving ≥ 10% body surface area, with disease severity PASI ≥ 10 at screening visit and visit
- •Psoriasis disease duration of at least 6 months prior to screening
- •Patients must be candidates for systemic psoriasis treatment or phototherapy
- •Patient must give informed consent and sign an approved consent form prior to any study procedures
- •Females of childbearing potential must have a negative pregnancy test result prior to enrollment and agree to use a highly effective method of birth control during the study. A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year).
排除标准
- •Patients with primary guttatae, erythrodermic, or pustular psoriasis and patients with drug-induced psoriasis
- •Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding of the medical examination (including vital signs and ECG), that in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data. This criterion provides an opportunity for the investigator to exclude patients based on clinical judgment, even if other eligibility criteria are satisfied. (Psoriatic arthritis is not considered an exclusion)
- •HIV infection or a known HIV-related Malignancy.
- •Chronic or acute hepatitis B and C, or carrier status. Patient with anti-HBc Ab and undetectable anti-HBs Ab should also be excluded.
- •Tuberculosis or a positive Tuberculin Skin Test (TST) for tuberculosis. Subjects previously received BCG vaccination or cannot receive TST can participate in the study after showing negative responses in Interferon-Gamma Release Assays (IGRA).
- •History of malignancy in the past 5 years or suspicion of active malignant disease except treated cutaneous squamous cell or basal cell carcinoma and carcinoma in situ of the cervix uteri.
- •History of allergy/hypersensitivity to a systemically administered biologic agent or its excipients
- •Use of biologic agents or investigational drug within 8-12 weeks prior to treatment, systemic anti-psoriatic medications or phototherapy within 4 weeks prior to treatment, or topical anti-psoriasis medications (except emollients) within 2 weeks prior to treatment
- •Intake of restricted medications or other drugs considered likely to interfere with the safe conduct of the study
- •Current alcohol abuse
- •Current drug abuse or positive drug screen at screening visit. Subjects with legitimate medically supervised uses of the drugs which are not excluded for other reasons can be enrolled.
- •Any blood donation or significant blood loss within 4 weeks prior to Visit 2
- •Excessive (e.g. competitive) physical activities (within 1 week prior to administration or during the trial)
- •Patients with any of the following laboratory values at screening and are considered clinically significant by the investigators:
- •Haemoglobin, hematocrit, white blood cell count, absolute lymphocyte or neutrophil count, or platelet count < LLN (below the lower limit of the reference normal range)
- •ALT, AST and/or total bilirubin > 2.5xULN
- •Serum creatinine > 1.5x ULN
- •Any clinically significant laboratory abnormalities other than those listed on Exclusion Criteria 14, based on the investigator's medical assessment at screening
结局指标
主要结局
75% reduction in the Psoriasis Area Severity Index (PASI 75)
时间窗: at week 10
The primary objective of this study is to investigate efficacy of AbGn-168H in patients with moderate to severe chronic plaque psoriasis following intravenous administration of multiple doses compared to placebo.
次要结局
- Number of participants with abnormal Physical Examination finding(At different time point for 20 weeks after the first treatment)
- Cmax(12 weeks after the first treatment)
- Number of participants with Vital Sign change(At different time point for 20 weeks after the first treatment)
- Number of participants with abnormal Clinical Laboratory parameters(At different time point for 20 weeks after the first treatment)
- T1/2(At different time point for 12 weeks after the first treatment)
- Number of participants with abnormal ECG finding(At different time point for 20 weeks after the first treatment)
- Number of participants with Adverse Event(At different time point for 20 weeks after the first treatment)
研究者
研究点 (28)
Loading locations...
相似试验
已完成
2 期
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis PatientsModerate to Severe Chronic Plaque PsoriasisNCT01855880AbGenomics B.V Taiwan Branch54
终止
2 期
Study of ACE-083 in Patients With Charcot-Marie-Tooth DiseaseCharcot-Marie-Tooth DiseaseNCT03124459Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA63
已完成
2 期
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During SleepEpileptic EncephalopathyContinuous Spike and Wave During SleepNCT04625101Neurocrine Biosciences24
已完成
2 期
Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout PatientsGoutHyperuricemiaNCT04040816Shanton Pharma Co., Ltd.40
进行中（未招募）
2 期
Emodepside Phase II Trial for Treatment of OnchocerciasisOnchocerciasisNCT05180461Drugs for Neglected Diseases578